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Abstract
Background: Kisspeptin is a neuropeptide known for its role in the hypothalamic regulation of the reproductive
axis. Following the recent description of kisspeptin and its 7-TM receptor, GPR54, in the dorsal root ganglia and
dorsal horns of the spinal cord, we examined the role of kisspeptin in the regulation of pain sensitivity in mice.
Results: Immunofluorescent staining in the mouse skin showed the presence of GPR54 receptors in PGP9.5-
positive sensory fibers. Intraplantar injection of kisspeptin (1 or 3 nmol/5 μl) induced a small nocifensive response
in naive mice, and lowered thermal pain threshold in the hot plate test. Both intraplantar and intrathecal (0.5 or 1
nmol/3 μl) injection of kisspeptin caused hyperalgesia in the first and second phases of the formalin test, whereas
the GPR54 antagonist, p234 (0.1 or 1 nmol), caused a robust analgesia. Intraplantar injection of kisspeptin
combined with formalin enhanced TRPV1 phosphorylation at Ser800 at the injection site, and increased ERK1/2
phosphorylation in the ipsilateral dorsal horn as compared to naive mice and mice treated with formalin alone.
Conclusion: These data demonstrate for the first time that kisspeptin regulates pain sensitivity in rodents and
suggest that peripheral GPR54 receptors could be targeted by novel drugs in the treatment of inflammatory pain.
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Background
Kisspeptin is a 54-amino acid peptide originally discov-
ered for its activity as metastasis-suppressor [1]. It is
encoded by the Kiss1 gene as a 145-amino acid precur-
sor protein and cleaved to a 54-amino acid protein as
well as into shorter products (kisspeptin-10,-13,-14)
known to play a critical role in the neuroendocrine reg-
ulation of reproduction [2-5].
In the brain, kisspeptin is localized not only in areas
involved in gonadotropin secretion, but also in other
regions such as the amygdala, hippocampus, and the
periacqueductal gray [6,7].
Its action is mediated by a 7-TM receptor named
GPR54, also known as KISS1R, which is coupled to
polyphosphoinositide hydrolysis via a Gq/11 GTP bind-
ing protein [2,8].
Loss-of-function mutations of GPR54 cause a non-Kall-
man variant of hypogonadotropic/hypogonadism in
humans (i.e. hypogonadotropic/hypogonadism without
anosmia) [2,9]. Interestingly, the expression of kisspeptin
and GPR54 is not restricted to the hypothalamus. Rela-
tively high levels of kisspeptin and GPR54 are found in
forebrain regions, such as the hippocampus and amygdala,
as well as in the periacqueductal grey [10]. The investiga-
tion of the extrahypothalamic functions of kisspeptin is
still at its infancy. Treatment with kainic acid increases
kisspeptin mRNA levels in the hippocampus, and kisspep-
tin enhances the amplitude of excitatory postsynaptic cur-
rents in granule cells of the hippocampal dentate gyrus
[6,7]. This suggests a potential role for kisspeptin in the
regulation of synaptic plasticity in the CNS. Recent find-
ings have shown an intense kisspeptin and GPR54 immu-
nostaining in dorsal root ganglia (DRG) neurons and in
lamina I and II of the dorsal horns of the spinal cord
[11,12]. The transcripts of kisspeptin and GPR54 are
up-regulated in DRG and dorsal horn neurons in the com-
plete Freund adjuvant (CFA) model of chronic inflamma-
tory pain [12], suggesting that kisspeptin may play a role
in mechanisms of nociceptive sensitization. However, how
precisely kisspeptin regulates pain sensitivity is obscure at
present.
We now report that peripheral or intrathecal injection of
kisspeptin causes hyperalgesia and induces biochemical
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changes that are consistent with mechanisms of peripheral
and central nociceptive sensitization.
Methods
Animals
Adult male CD1 mice (Charles River, Calco, CO, Italy),
129S6/Sv/Ev wild-type, and 129S6/Sv/Ev Gpr54- knock-
out mice [13] aged between 8 and 9 weeks were used in
these experiments. Mice were housed 10 animals per
cage with food and water ad libitum in standard 12/12 h
light/dark cycle, for a period of 2 weeks before testing.
All experiments were carried out according to the
recommendations of Institutional Animal Care and Use
Committee (IACUC). All efforts were made to minimize
animal suffering and to reduce the number of animals
used.
Drug administration
Kisspeptin (Calbiochem Merck KGaA, Darmstadt, Ger-
many) was dissolved in 5% DMSO and injected intrathe-
cally (3 μl) or subcutaneously (5 μl) into the plantar
surface of the right hind paw using a 10 μl luertip-syringe
(Hamilton) fitted with a 30-gauge needle. p234 (Sigma-
Aldrich, St. Louis, MO) was dissolved in phosphate buf-
fered saline (PBS) and injected in a volume of 3 μl for
intrathecal administration or 5 μl for intraplantar
administration.
Behavioral experiments
Hot plate test
The hot plate test (Ugo Basile, Italy) was used to asses ther-
mal sensitivity. CD1 mice were placed onto the hot plate at
the temperature of 55 ± 0.1°C. Paw withdrawal thresholds
were determined in the hind paws of ipsilateral hind limb.
Animals were kept on the plate until the first sign of ipsi-
lateral paw lift or lick was recorded as basal withdrawal
latency (pre-drug latency). A maximum cut-off paw with-
drawal latency of 20 seconds was chosen to prevent tissue
damage (cut-off time). Post-dose thresholds were taken at
5, 15, 30, and 60 minutes after drug administration (post-
drug latency). For each animal, results were expressed as
the percentage maximum possible effect (%MPE) calcu-
lated using the following formula: [(post-drug latency -
pre-drug latency)/(cut-off time - pre-drug latency)] × 100.
Formalin test
Inflammatory pain was assessed using the formalin test.
Ten μl of a 5% formalin solution was injected subcuta-
neously into the plantar surface of the right hind paw of
CD1 mice. After the injection, mice were immediately
placed in a plexiglas box (20 × 15 × 15 cm) surrounded
by mirrors to allow the observation of nociceptive
responses that include licking, lifting and shaking of the
injected paw. Tests were performed between 08:00 h and
12:00 h to minimize variability. Mice were observed for
1 hour. Formalin scores were separated into two phases,
phase I (0-10 min) and phase II (15-45 min). The mean
behavioural score was calculated in blocks of 5 min for
each of the two phases. A mean response was then calcu-
lated for each phase.
Spontaneous pain
CD1 mice that received intraplantar injection of kisspep-
tin or vehicle were placed in a cage immediately after
the injection, and the duration of hind paw lifting and
licking during the first 5 minutes were measured.
All behavioral tests were analyzed by observers blind
to the treatment of the animals.
Immunohistochemistry
Skin biopsies
Animals were euthanized with chloral hydrate (320 mg/kg
i.p.). 2.5-mm punch skin biopsies from the plantar surface
of the hind paws were performed and fixed in Zamboni
fixative (2% paraformaldehide, 15% picric acid saturated
aqueous solution, 0.1 M phosphate buffer pH 7.4) for
24 hours. Biopsies were cryoprotected with 20% sucrose in
PBS overnight at 4°C. Sections of 10 μm were cut at the
cryostat and mounted on glass slides for immunohisto-
chemical analysis.
Immunohistochemistry procedures were performed as
previously described [14]. Double immunofluorescence
was performed in skin biopsies from CD1 male mice incu-
bating sections overnight with polyclonal rabbit anti-
human PGP 9.5 (1:1000; AbD Serotec, Kidlington, UK)
and goat polyclonal anti-GPR54 (1:20; Santa Cruz Biotech-
nology, Santa Cruz, CA) and then for 1 h with secondary
fluorescein anti-rabbit (1:100; Vector Laboratories, Burlin-
game, CA) and Cy3 anti-goat (1:400; Chemicon, Billerica,
MA) antibodies. Control staining was performed without
the primary antibodies.
Immunostaining was performed in skin biopsies from
male 129S6/Sv/Ev wild-type and 129S6/Sv/Ev Gpr54-
knock-out mice [13] to test the specificity of the anti-
GPR54 antibody. Tissue sections were incubated overnight
with goat polyclonal anti-GPR54 (1:20; Santa Cruz Bio-
technology, Santa Cruz, CA) and then for 1 h with second-
ary biotin-coupled anti-goat (1:100; Vector Laboratories,
Burlingame, CA). SG (SG substrate kit; Vector Labora-
tories, Burlingame, CA, USA) chromogen was used for
detection.
Spinal cord
CD1 mice (n = 5 per group) were used. 3 min after kis-
speptin (3 nmol) or vehicle (DMSO) were co-injected
with formalin in the right hind paw and lumbar spinal
cords were removed and fixed in formalin (4%) overnight,
transferred in 70% ethanol and included in paraffin. Ten
serial sections were cut and used for immunohistochem-
ical analysis. Deparaffinized sections were treated with
10 mmol/L citrate buffer, pH 6.0, and heated by
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microwave for 10 minutes for antigen unmasking.
Sections were soaked in 3% hydrogen peroxide to
block endogenous peroxidase activity. Tissue sections
were incubated overnight with monoclonal rabbit anti-
body anti-phospho-p44/42 (Erk1/2) (Thr202/Tyr204)
(D13.14.4E)XP™ (1:200; Cell Signaling Technology,
Denver, MA, USA) and then for 1 h with secondary
biotin-coupled anti-rabbit (1:200; Vector Laboratories).
3,3-Diaminobenzidine tetrachloride was used for detec-
tion. Control staining was performed without the primary
antibodies.
Densitometric analysis of p-ERK immunoreactivity
Intensity of p-ERK immunoreactivity was quantified by
measuring the optical densities of the outer laminae of the
dorsal horn in the stained sections relative to the back-
ground (ventral horn). Images were acquired using a com-
puter-based microdensitometer (NIH Image Software,
Bethesda, MD, USA). Values were the mean of measure-
ments made on ten sections (10 μm) sampled 1 into a 3
series spanning the extent of the L4-L5 spinal cord.
Western blot analysis
CD1 Mice were sacrificed 3 min following treatment and
skin lysates of all groups were processed in western blot.
Skin homogenates were obtained as previously described
[15]. Ten μg of total protein were separated by 10% SDS-
polyacrylamide gel electrophoresis and electrophoretically
transferred onto protein-sensitive nitrocellulose mem-
branes (Criterion blotter; Bio-Rad Laboratories, Hercules,
CA). The membranes were blocked in Odyssey blocker
(LI-COR Biosciences, Lincoln, NE) for 1 h, and the follow-
ing primary antibodies were used: anti-TRPV1 (phospho
S800) polyclonal antibody (1:400, Abnova, Aachen, Ger-
many); anti-actin monoclonal antibody (1:1000, Sigma).
Secondary antibodies were: goat anti-rabbit (IRD800CW)
and goat anti-mouse (Alexa 680, LI-COR, Bioscience) anti-
bodies. Proteins were detected with the Odyssey Infrared
Fluorescence Imaging System (LI-COR).
Results
Knowing that the kisspeptin receptor, GPR54 (KISS1R), is
present in DRG neurons [12], we performed immuno-
fluorescent analysis to examine whether the receptor was
also present in peripheral nociceptors. We focused on the
peripheral role of kisspeptin in the modulation of acute
and inflammatory pain. First we examined the specificity
of the GPR54 antibody in skin biopsies from GPR54 KO
mice. No immunostaining was seen in sensory nerve term-
inals of GPR54 KO mice (Figure 1). The nature of the
nonspecific staining seen in the outer portion of the skin
of GPR54 KO mice is unknown. In punch skin biopsies
from the mouse hind paw, sensory fibers ascending verti-
cally between the keratinocytes to reach the stratum cor-
neum of the epidermis were identified by fluorescent
immunostaining for the neuron-specific ubiquitin hydro-
lase, PGP9.5 [14] (Figure 2A). These fibers also expressed
GPR54, as shown by double fluorescence immunostaining
(Figure 2B, C). Behavioral experiments were performed
after peripheral (intraplantar) and central (intrathecal)
administration of kisspeptin at doses ranging from 0.1 to 3
nmol [16]. We first examined the effect of intraplantar
injection of kisspeptin on nocifensive behavior in naïve
mice. Nocifensive behavior consisting of licking, flinching
and shaking of the injected paw was evaluated after a sin-
gle injection of kisspeptin (3 nmol/5 μl) or vehicle into the
plantar surface of the right hind paw. The time spent in
nocifensive behavior was recorded for 5 min after the
injection. Intraplantar injection of kisspeptin (3 nmol/5 μl)
induced brief nocifensive behavior that lasted for about 5-
15 seconds, whereas no signs of pain were seen in vehicle-
Figure 1 Immunostaining for the kisspeptin receptor, GPR54, in the mouse skin of GPR54 WT and KO mice. Representative
immunostaining showing the specificity of the GPR54 antibody in the peripheral nerve endings of the mouse skin of GPR54+/+ mice (left panel).
No immunostaining is observed in GPR54-/- mice (right panel). Scale bar 100 μm. The insert shows an immunopositive fiber at higher
magnification (scale bar = 20 μm).
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injected mice (Figure 3A). We then assessed the effect of
kisspeptin on acute thermal pain using the hot plate test.
Intraplantar injection of kisspeptin (3 nmol/5 μl) signifi-
cantly reduced paw withdrawal latency in response to heat
as compared to intraplantar injection of vehicle (Figure
3B), whereas no differences were observed after p234
injection (0.1 nmol/5 μl) (Figure 3C).
For the assessment of inflammatory pain, mice were
subjected to the formalin test, 15 min after intraplantar
(0.1, 1 and 3 nmol/5 μl) or intrathecal (0.1, 0.5 and
1 nmol/3 μl) injection of kisspeptin. Intraplantar injection
of formalin elicits a biphasic nocifensive response charac-
terized by licking, lifting and shaking of the injected paw.
The first phase of the formalin test, starting immediately
after formalin injection and lasting for about 10 min,
represents a form of acute pain elicited by direct activation
of nociceptors. The second phase of the test (occurring
approximately 15-45 min after formalin injection) reflects
the development of nociceptive sensitization in the dorsal
horns of the spinal cord [17,18]. Intraplantar injection of
both 1 and 3 nmol/5 μl of kisspeptin (15 min prior to for-
malin injection) caused hyperalgesia in the first and sec-
ond phases of the formalin test whereas no effects were
observed at the lower dose of 0.1 nmol/5 μl (Figure 4). We
also assessed the effect of the selective GPR54 antagonist,
peptide 234 (p234) [19] in the formalin test. As opposed to
kisspeptin, intraplantar injection of p234 (1 nmol/5 μl;
15 min prior to formalin) significantly reduced nocifensive
behavior (Figure 4B). A lower dose of p234 (0.1 nmol/5 μl)
induced a trend to an analgesic effect, which was not statis-
tically significant (Figure 4B). We also examined whether
intrathecal injection of kisspeptin or p234 could affect noci-
fensive behavior in the formalin test. Kisspeptin injected
intrathecally at the dose of 1 nmol/3 μl, 10 min prior to
Figure 2 Double immunofluorescent staining for the kisspeptin receptor, GPR54, and PGP9.5 in the mouse skin. Immunofluorescent
staining of PGP9.5 and GPR54 is shown in (A) and (B), respectively. Co-immunolocalization is shown in (C) (see arrowheads). Scale bar 20 μm.
Figure 3 Intraplantar injection of kisspeptin lowers pain threshold in the hot plate. The nocifensive response to intraplantar injection of
kisspeptin (3 nmol/5 μl) in naïve mice is shown in (A). Data are means ± S.E.M of 6 mice, and refer to the number of sec spent in licking
behavior in the first 5 min following injection. *p < 0.05 (Student’s t test) vs. mice injected with vehicle. Data obtained in the hot plate test are
shown in (B). For each animal, the percentage maximum possible effect (%MPE) was calculated using the following formula: [(post-drug latency)
- (pre-drug latency)/(cutoff time) - (pre-drug latency)] × 100. Data are means ± S.E.M. of 6 to 8 mice. *p < 0.05, two-way ANOVA followed by
Fisher’s post hoc test. PWL, Paw-withdrawal latency.
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intraplantar injection of formalin, significantly increased
nocifensive behavior in the first and second phases of the
formalin test. A lower dose of kisspeptin (1 nmol/3 μl)
caused hyperalgesia in the first phase, and a non-significant
trend to hyperalgesia in the second phase of the test (Figure
4C). When injected intrathecally, compound p234 was
analgesic at doses of 0.1 and 1 nmol/3 μl in both phases of
the formalin test (Figure 4D). The hyperalgesic activity of
kisspeptin in both phases of the formalin test led us to
investigate whether the peptide could induce biochemical
changes that were consistent with mechanisms of periph-
eral and central sensitization. We therefore examined
TRPV1 channel phosphorylation in the skin of the hind
paw, and activation of ERK1/2 in the dorsal horns of the
spinal cord in mice subjected to intraplantar injection of
formalin preceded by kisspeptin or vehicle. Immunoblot
analysis with anti-phosphorylated TRPV1 antibodies
showed a single band at the expected molecular size of 95
kDa. We observed that in mice pretreated with vehicle,
intraplantar injection of formalin slightly increased the
levels of phosphorylated TRPV1 in the ipsilateral hind paw
as compared to naïve mice. This effect was largely amplified
in mice pretreated with kisspeptin (3 nmol/5 μl, 15 min
prior to formalin injection) (Figure 5). Activation of
the mitogen activated protein kinase (MAPK) pathway
was examined by immunohistochemical analysis of phos-
phorylated ERK1/2 in the dorsal horns of the spinal cord
after intraplantar injection of formalin preceded by vehicle
Figure 4 Effect of intraplantar or intrathecal injection of kisspeptin or the GPR54 antagonist, p234, in the formalin test. Data obtained
with intraplantar (i.pl.) injection of kisspeptin (1 or 3 nmol/5 μl) or p234 (0.01 or 0.1 nmol/5 μl) on the first (0-10 min) and second (15-45 min)
phases of the formalin test are shown in (A) and (B), respectively. Drugs were injected 15 min prior to the intraplantar injection of formalin. Data
obtained with intrathecal (i.t.) injection of kisspeptin (0.5 or 1 nmol/3 μl) or p234 (0.1 or 1 nmol/3 μl) are shown in (C) and (D), respectively. Data
are means + S.E.M. of 8-12 mice per group. *p <0.05 vs. the respective groups of mice injected with vehicle (one-way ANOVA followed by
Fisher’s post hoc test).
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or kisspeptin. Formalin injection preceded by vehicle
slightly enhanced phosphorylated ERK1/2 immunostaining
in the dorsal horn ipsilateral to the injection side as com-
pared to the contralateral dorsal horn or the dorsal horns
of naïve mice (Figure 6). Pretreatment with kisspeptin (3
nmol/μl) dramatically enhanced the expression of phos-
phorylated ERK1/2 in the ipsilateral dorsal horn (Figure 6).
Discussion
These data offer the first demonstration that kisspeptin, a
peptide known for its role in the regulation of the
hypothalamic-pituitary-gonadal axis, lowers pain threshold
and enhances nocifensive behavior in mice. Immunohisto-
chemical analysis showed the presence of the kisspeptin
receptor, GPR54, in peripheral sensory fibers, a finding
Figure 5 Intraplantar injection of kisspeptin amplified the increase in TRPV1 phosphorylation in the skin of mice treated with
formalin. A representative immunoblot of (Ser800)-phosphorylated TRPV1 in the skin of naïve mice and mice injected with formalin in the
absence or presence of kisspeptin (3 nmol/5 μl) is shown in (A). Densitometric analysis is shown in (B), where values are means + S.E.M. of 4
determinations. *p < 0.05 vs. naïve mice, #p < 0.05 or vs. mice treated with formalin alone (one-way ANOVA followed by Fisher’s post hoc test).
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that is consistent with the detection of GPR54 mRNA and
protein in DRG neurons [11,12]. The lack of staining in
GPR54 KO mice indicates that GPR54 is present in per-
ipheral nociceptors explaining the hyperalgesia caused by
intraplantar injection of kisspeptin in the hot plate and
formalin test. We wish to highlight that intraplantar kis-
speptin induced only a small nocifensive response on its
own, suggesting that a main action of kisspeptin is to
amplify pain sensitivity in response to noxious stimuli.
Intraplantar injection of the GPR54 antagonist, p234,
caused a robust analgesia in the formalin test, suggesting
that endogenous kisspeptin acts extracellularly to activate
GPR54 receptors during inflammatory pain. Kisspeptin is
present in DRG neurons, where it co-localizes with
Figure 6 Intraplantar injection of kisspeptin increased ERK phopshorylation in the ipsilateral dorsal horn of the spinal cord. (A)
Immunohistochemical analysis of phosphorylated-ERK1/2 in the dorsal horns of the spinal cords of naïve mice and mice treated with formalin in
the absence or presence of kisspeptin (3 nmol/5 μl) is shown. Contra = contralateral; ipsi = ipsilateral. Scale bar = 50 μm. The insert shows an
immunopositive neuron at higher magnification (scale bar = 10 μm). (B) Densitometric analysis of p-ERK immunoreactivity in the superficial
laminae of the dorsal horn. *p < 0.05 vs. contralateral values; #p < 0.05 vs. formalin alone values (one-way ANOVA + Dunnett’s Multiple
Comparison Test).
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isolectin B4 and calcitonin gene-related peptide, and its
expression is up-regulated by chronic inflammatory pain
[12]. It is likely that kisspeptin is released from peripheral
nociceptors in response to noxious stimuli, therefore
behaving as an autocrine/paracrine factor to promote per-
ipheral nociceptive sensitization. Whether other cells can
produce and secrete kisspeptin during inflammation is
unknown at present. Phosphorylation of the TRPV1 ion
channel is a key event in mechanisms of peripheral noci-
ceptive sensitization [20-22]. The TRPV1 receptor can be
phosphorylated by multiple protein kinases, including pro-
tein kinase A, protein kinase C (PKC), calcium/calmodu-
lin-dependent protein kinase II, and SRC [23-34]. In,
particular, PKC phosphorylates TRPV1 at Ser-502 and
Ser-800, thus amplifying ion channel activity [31,35-37].
Intraplantar kisspeptin caused a robust increase in
(Ser800)-TRPV1 phosphorylation, an effect that was likely
mediated by the activation of the GPR54 receptor, with
ensuing stimulation of inositol phospholipid hydrolysis,
diacylglycerol formation, and PKC activation [2,8]. Thus,
kisspeptin might act similarly to other hyperalgesic mole-
cules that activate Gq-coupled receptors and phosphory-
late TRPV1 channels in peripheral nociceptors, such as
bradykinin, group-I mGlu receptor agonists, P2Y2 recep-
tor agonists, EP1 receptor, and prokineticin [28,38-48].
Hyperalgesia by kisspeptin and analgesia by p234 were
also seen in the second phase of the formalin test, which
reflects the development of central nociceptive sensitiza-
tion in the dorsal horns of the spinal cord [17,18]. Central
nociceptive sensitization is mediated by a series of
mechanisms that ultimately lead to an enhancement of
excitatory transmission at the synapses between primary
afferent fibers and second order sensory neurons in the
dorsal horns of the spinal cord [24]. The relevance of the
MAPK pathway in the development of central sensitiza-
tion has been highlighted in a recent review [48]. Intra-
plantar injection of formalin is known to induce a rapid
phosphorylation of ERK1/2 in the spinal cord, which has
been causally related to the increase in nocifensive beha-
vior seen in the second phase of the formalin test [49].
Pharmacological activation of mGlu1 and mGlu5 recep-
tors, which also couple to the Gq protein just like GPR54
[50], can also enhance ERK1/2 phosphorylation in the
spinal cord [51]. Activation of GPR54 by kisspeptin has
been shown to stimulate the ERK/MAPK pathway both in
recombinant expression systems and hypothalamic
explants [52,53]. Intraplantar injection of kisspeptin mark-
edly amplified ERK1/2 phosphorylation induced by forma-
lin in the ipsilateral dorsal horn, evidence that nicely
supports the behavioral data obtained with kisspeptin in
the second phase of the formalin test. Interestingly, kis-
speptin retained the hyperalgesic activity (and p234 the
analgesic activity) when injected by the intrathecal route.
Thus, it is likely that the modulation of pain sensitivity by
GPR54 extends beyond peripheral nociceptors. Effects of
kisspeptin on different receptors cannot be excluded. In
particular it has been reported that kisspeptin can also
bind neuropeptide FF (NPFF) receptors [54]. However in
our hands intrathecal injection of kisspeptin lowers pain
threshold, whereas intrathecal injection of NPFF is known
to cause analgesia [55], thus the effect of kisspeptin in the
spinal cord is likely mediated by the activation of the
GPR54 receptor excluding an interaction of kisspeptin
with NPFF receptors.
The presence of GPR54 receptor in the amygdala [56]
may suggest that kisspeptin acts also at higher brain cen-
ters that control the affective components of pain and
contributes to the top-down regulation of pain threshold.
Conclusions
In conclusion, our data disclose a new aspect in the
physiology of kisspeptin and suggest that peripheral
GPR54 receptor antagonists (lacking potential hypotha-
lamic side effects) can be developed as new drugs for
the treatment of inflammatory pain. In addition, it will
be interesting to explore whether individuals with hypo-
gonadotropic hypogonadism due to inactivating muta-
tions of GPR54 show alterations in the sensitivity to
pain.
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